Table 1

Patient baseline characteristics

CharacteristicsN=57
Age (years), median (Q1–Q3)56.5 (45.8–63.8)
Sex, n (%)
 Male30 (52.6)
 Female27 (47.4)
ECOG PS, n (%)
 020 (35.1)
 137 (64.9)
Primary tumor location, n (%)
 Right-sided31 (54.4)
 Left-sided25 (43.9)
 Right and left location1 (1.8)
Mutation status, n (%)
RAS/RAF wild type19 (33.3)
RAS mutation28 (49.1)
BRAF mutation10 (17.5)
Origin of MMR deficiency, n (%)
 Lynch-related32 (56.1)
 Known germline mutation19 (59.4)
 Sporadic16 (28.1)
 Unknown9 (15.8)
Number of metastatic sites, n (%)
 116 (28.1)
 225 (43.9)
 >216 (28.1)
Number of prior lines, n (%)
 15 (8.8)
 224 (42.1)
 >227 (47.4)
 Missing1 (1.8)
Prior treatments, n (%)
 5-FU/capecitabine57 (100.0)
 Oxaliplatin57 (100.0)
 Irinotecan55 (96.5)
 Trifluridine/tipiracil4 (7.0)
 Regorafenib5 (8.8)
 Bevacizumab/aflibercept33 (57.9)
 Cetuximab/panitumumab26 (45.6)
  • ECOG PS, The Eastern Cooperative Oncology Group Performance Status; 5-FU, 5-fluorouracil; MMR, DNA mismatch repair.